Trade

Glenmark Pharmaceuticals share price

Balanced risk
  • 30%Low risk
  • 30%Moderate risk
  • 30%Balanced risk
  • 30%High risk
  • 30%Extreme risk
  • ₹1,974.15(0.56%)
    December 4, 2025 09:01:00 AM IST
    • NSE
    • BSE
  • Vol : 437.05 K (NSE + BSE)
    Last 20 day avg : 1.34 M

Glenmark Pharmaceuticals is trading 0.56% upper at Rs 1,974.15 as compared to its last closing price. Glenmark Pharmaceuticals has been trading in the price range of 1,983.00 & 1,958.80. Glenmark Pharmaceuticals has given 22.66% in this year & 1.53% in the last 5 days. Glenmark Pharmaceuticals has TTM P/E ratio 54.57 as compared to the sector P/E of 32.51.There are 9 analysts who have initiated coverage on Glenmark Pharmaceuticals. There are 5 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 610.35 Crores in its last quarter.Listed peers of Glenmark Pharmaceuticals include Alkem Laboratories (-2.54%), Glaxosmithkline Pharmaceutical (-0.69%), Glenmark Pharmaceuticals (0.56%).The Mutual Fund holding in Glenmark Pharmaceuticals was at 16.31% in 30 Sep 2025. The MF holding has increased from the last quarter. The FII holding in Glenmark Pharmaceuticals was at 20.73% in 30 Sep 2025. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Dec 05, 2025, 03:32 AM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.49
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.28
    Higher than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.25
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    6.27
    Higher than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    54.95
    Higher than historical values
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    15.29
    Indicates overvaluation
Price range
Day Range
Lowest
1,958.80
Highest
1,983.00
52 week range
Lowest
1,274.70
Highest
2,286.15
Glenmark Pharmaceuticals News
Glenmark Pharmaceuticals Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Alkem Laboratories
Neutral
5,611.65-2.5468,358.3026.624.810.934.83
Glaxosmithkline Pharmaceutical
Bearish
2,509.30-0.6942,619.4660.5328.671.270.13
Glenmark Pharmaceuticals
Bullish
1,974.150.5655,630.3637.955.690.147.90
Biocon
Neutral
388.25-5.3451,907.6147.702.080.1359.81
Laurus Labs
Bullish
1,012.65-0.6254,705.89129.299.150.1615.82
Mutual Fund Ownership
View all
Mirae Asset Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 147.69
  • % of AUM 5.49
HDFC Pharma and Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 70.16
  • % of AUM 4.12
Tata Nifty MidSmall Healthcare Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 5.40
  • % of AUM 3.95
Motilal Oswal Nifty MidSmall Healthcare Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 0.96
  • % of AUM 3.94
UTI Healthcare Fund Regular Plan Growth
NA
  • Amount Invested (Cr.) 40.11
  • % of AUM 3.78
Glenmark Pharmaceuticals Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2025-11-14Quarterly Results
2025-09-26Interim Dividend
2025-08-14Quarterly Results
2025-05-23Audited Results & Final Dividend
2025-02-14Quarterly Results
About the company Glenmark Pharmaceuticals
  • IndustryBiotechnology & Drugs
  • ISININE935A01035
  • BSE Code532296
  • NSE CodeGLENMARK
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
  • Management Info
  • Glenn SaldanhaExecutive Chairman of the Board, Managing Director
  • Anurag MantriGlobal Chief Financial Officer, Executive Director
  • Harish KuberCompliance Officer, Company Secretary
  • Cherylann PintoExecutive Director - Corporate Services
Glenmark Pharmaceuticals Share Price FAQs

Glenmark Pharmaceuticals is trading at 1974.15 as on Thu Dec 04 2025 03:31:00. This is 0.56% upper as compared to its previous closing price of 1974.15.

The market capitalization of Glenmark Pharmaceuticals is 55630.36 Cr as on Thu Dec 04 2025 03:31:00.

The average broker rating on Glenmark Pharmaceuticals is Buy. The breakup of analyst rating is given below -

  • 5 analysts have given a strong buy rating
  • 2 analysts have given a buy rating
  • 1 analysts have given a hold rating
  • 0.00 analysts have given a sell rating
  • 1 analysts have given a strong sell rating

The 52 wk high for Glenmark Pharmaceuticals is 2286.15 whereas the 52 wk low is 1274.70

Glenmark Pharmaceuticals can be analyzed on the following key metrics -

  • TTM P/E: 54.57
  • Sector P/E: 32.51
  • Dividend Yield: 0.25%
  • D/E ratio: 0.13

Glenmark Pharmaceuticals reported a net profit of 1047.10 Cr in 2025.

The Mutual Fund Shareholding was 16.31% at the end of 30 Sep 2025.

Quick Links
EQUITY QUICK LINKS
Glenmark Pharmaceuticals QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Business News/Market/Market Stats/  Glenmark Pharmaceuticals share price
✕

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.